Cutaneous Lupus Erythematosus Skin Punch Biopsy

About Cutaneous Lupus Erythematosus Skin Punch Biopsy

Cutaneous Lupus Erythematosus Skin Punch Biopsy for Autoimmune Dermatology Research

Cutaneous Lupus Erythematosus Skin Punch Biopsy samples are collected from IRB-consented donors with a clinically confirmed diagnosis of cutaneous lupus erythematosus (CLE). Biopsies are taken by licensed clinicians under aseptic conditions and, where frozen material is requested, are frozen within 4 hours of collection. Lesional, non-lesional, and sun-protected sites can be requested. These specimens support histopathological, immunological, and molecular research into the autoimmune tissue injury that defines CLE.

Why Skin Tissue for Cutaneous Lupus Research

CLE is an autoimmune disease in which the target organ is the skin. The defining lesion is an interface dermatitis: a lymphocytic infiltrate at the dermal-epidermal junction with vacuolar change and apoptosis of basal keratinocytes. That pathology exists in the tissue and cannot be reconstructed from blood alone.

• Interface dermatitis, basement membrane thickening, follicular plugging, and dermal mucin are assessable only in intact tissue architecture, making punch biopsy the reference specimen for CLE histopathology.
• Direct immunofluorescence on lesional skin demonstrates immunoglobulin and complement deposition at the dermal-epidermal junction — the basis of the lupus band test.
• Lesional CLE skin shows a prominent type I interferon signature, with recruitment of plasmacytoid dendritic cells and expression of interferon-inducible chemokines; this is the rationale for interferon-directed and JAK-directed therapeutic programmes.
• CD8+ cytotoxic T cells accumulate at the junction and mediate keratinocyte killing; their spatial position relative to the basal layer is informative and is lost on dissociation.
• CLE is characteristically photosensitive, and ultraviolet exposure drives keratinocyte apoptosis and autoantigen exposure — a mechanism best interrogated in skin explants or fixed tissue.
• Paired lesional and non-lesional biopsies from the same donor provide an internally controlled comparison that separates disease-driven change from inter-individual variation.

Donor Stratification Available

• CLE subtype: acute (ACLE), subacute (SCLE), or chronic/discoid (DLE), including scarring and dyspigmented lesions
• Biopsy site: lesional, perilesional, non-lesional exposed, or sun-protected skin
• Serology: ANA titre and pattern, anti-Ro/SSA, anti-La/SSB, anti-dsDNA where documented
• Presence or absence of concurrent systemic lupus erythematosus
• Disease activity and damage assessment, including CLASI scoring where captured
• Treatment status: topical or intralesional corticosteroid, antimalarial (hydroxychloroquine), systemic immunosuppressant, biologic, or treatment-naive
• Fitzpatrick skin type, smoking status, and photosensitivity history
• Matched healthy controls available

Product Features

• Research Use Only (RUO), fresh or frozen skin punch biopsies
• Samples are frozen (if requested) within 4 hours of collection
• Clinically confirmed cutaneous lupus erythematosus donors
• Collected by licensed clinicians under aseptic conditions
• Lesional and non-lesional sites available from the same donor on request
• Processed and shipped same-day where applicable
• IRB-approved protocols and electronic informed consent

De-identified Donor Data

• Verified diagnosis of cutaneous lupus erythematosus and subtype where documented
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and lesion site
• Serology and disease activity data available upon request

Applications

• Histopathological grading of interface dermatitis and adnexal involvement
• Direct immunofluorescence for immunoglobulin and complement deposition
• Interferon signature scoring by bulk or spatial transcriptomics
• Multiplex immunohistochemistry and imaging mass cytometry of infiltrating T cells and dendritic cells
• Single-cell and spatial profiling of keratinocyte, fibroblast, and immune compartments
• Target validation for interferon-pathway, JAK, and B cell-directed therapeutics
• Ex vivo skin explant assays, including ultraviolet challenge models
• Biomarker discovery differentiating CLE subtypes and predicting scarring outcomes

Other Cutaneous Lupus Erythematosus Specimen Types

• Cutaneous Lupus Erythematosus Serum
• Cutaneous Lupus Erythematosus Plasma
• Cutaneous Lupus Erythematosus Whole Blood
• Cutaneous Lupus Erythematosus PBMC
• Cutaneous Lupus Erythematosus Leukopak
• Cutaneous Lupus Erythematosus Bulk Plasma

Compliance and Quality Assurance

• IRB-approved collections and SOP-driven processing
• 21 CFR Part 11-compliant electronic informed consent
• HIPAA-compliant donor data management

Ordering & Customization

Cutaneous Lupus Erythematosus Skin Punch Biopsy samples can be shipped ambient, refrigerated, or on dry ice. For pricing, availability, orders outside the United States, or regulatory documentation, please contact learnmore@sanguinebio.com. To browse other disease states and biopsy formats, visit our human skin punch biopsy page.